Palforzia® not recommended for use within NHSScotland
- 15 December 2022
- Healthcare News
- News
The Scottish Medicines Consortium (SMC) has completed its assessment of Arachis hypogaea L., semen (peanuts) (Palforzia®),and have confirmed this is not recommended for use within NHSScotland.
They concluded that treatment with Palforzia® is expected to be resource intensive with food allergy clinics needing to be reconfigured or newly setup to build capacity in providing oral immunotherapy. It was felt that there is a high degree of uncertainty regarding the proportion of individuals who would include peanuts in their diet, the proportion who would revert to avoidance only and the rate at which this occurs after cessation of Palforzia®. SMC clinical experts agreed long-term outcomes are uncertain.
Sarah Baker, Head of Health Policy and Developments, Anaphylaxis UK said:-
“We are disappointed that SMC have decided not to approve Palforzia in Scotland. Anaphylaxis UK works with many parents of children with peanut allergy, and we know it is challenging to manage. New treatment options can help to mitigate the risks of serious allergies”
